Icon times
Divis Labs Limited Q4FY21 Conference Call Highlights

Divis Labs Limited Q4FY21 Conference Call Highlights

Published on 09 June 2021 .Views 83 .Comments 0
Share On

FY21 Performance:

  • Assets worth Rs 1,179 crores have been capitalized during the current financial year
  • Capital work-in-progress worth Rs 710 crores in projects of custom synthesis and generic products is still in progress
  • Consolidated income for the year is Rs 7,032 crores reflecting a growth of 26% over the previous year
  • Profit before tax grew 47% and is Rs 2,666 crores for the year
  • PAT during the year is Rs 1,984 crores reflecting a growth of 44% over the previous year.
  • At the end of the current year, cash on the book is Rs 2,156 crores, receivables Rs 1,677 crores and inventory is Rs 2,145 crores
  • Forex loss of Rs 4 crores for the year
  • Exports for the year is 88%
  • Constant currency growth for the year has been 24%
  • Nutraceutical business for the year amounted to Rs 595 crores





Q4FY21 Performance:

  • The consolidated total income is Rs 1,812 crores during the quarter reflecting a growth of 24% over the corresponding quarter of the previous year.
  • Profit before tax grew by 42% for the quarter and is Rs 669 crores
  • PAT is Rs 502 crores during the quarter reflecting growth of 29% year-on-year
  • Assets worth Rs 173 crores have been capitalized during the quarter
  • Forex gain of Rs 4 crores for the quarter
  • Exports for the quarter is 90%
  • Constant currency growth for the quarter has been 31%
  • Nutraceutical business for the quarter amounted to Rs 156 crores



Research & Development and Products:

  • New major fast track custom synthesis project with innovator is commercialized
  • Kakinada project will commence soon as the court has dismissed all the claims.
  • New generic molecules with current dosage sale of $20 billion are -selected, technologies developed, validations and regulatory submission are under progress
  • Commercial shipments have taken place from Stream 1. Validation started at Stream 2 and will be followed by commercial production at DCV-SEZ.
  • A third stream of this new API was planned at Unit 1 as the innovator has given a clearance of supply to domestic VL partners.




FY22 Outlook:

  • Aims that the ratio of API versus synthesis to be 50:50, currently the ratio is 60:40
  • To apply tools of green chemistry, highest yields, highest recovery, least waste, consuming less raw materials and atom efficiency


private article suscription area icon

You like to know more. We like that!

Please subscribe Model Portfolio Plan to get access of all premium model portfolio articles Only at Rs. 9,999.00/Year.

Please login to view this free article.

This blog is available only for logged in users, please register and get access to view this article.

Recently Uploaded

premium Premium
free Free
Chat on WhatsApp
Caret UP Arrow
InvestYadnya Support
Typically replies in minutes
InvestYadnya Support
Hi there
Welcome to InvestYadnya.
We are available to assist you on WhatsApp.
Please click on the button below to chat with us.
(10 AM to 7 PM IST)
Chat with InvestYadnya